Compare Lucid Group Inc (LCID) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs Twist Bioscience Corp — how do they compare? Lucid Group Inc trades at $7.15 (market cap $2.87B), while Twist Bioscience Corp trades at $87.82 (market cap $5.84B). The key difference: Twist Bioscience Corp is far larger — about 2× Lucid Group Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.
| LCID | TWST | |
|---|---|---|
Market Cap | $2.87B | $5.84B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.30 | $102.88 |
52-Week Low | $4.62 | $24.16 |
Enterprise Value | $5.34B | $5.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $7.33, down 0.41% on the day, amid mixed technical signals and severe fundamental challenges. The stock shows a bullish moving average trend but bearish oscillators, with RSI at 70.77 suggesting overbought conditions. Financially, the company reported a net loss of $2.70 billion on $1.35 billion revenue in 2025, with negative margins across gross profit (-95.6%) and net income (-239.81%). Recent news highlights class-action lawsuits and bankruptcy rumors, though management denies financial distress.
The outlook remains highly speculative with significant execution and liquidity risks. Analyst consensus is cautious, with 66.7% hold ratings and a $10.50 price target implying limited upside. Investment appeal hinges on Lucid's ability to achieve profitability and scale production, but current financials and legal overhangs present substantial headwinds for near-term performance.
Twist Bioscience (TWST) trades at $90.98, down 3.06% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Recent Q2 2026 earnings beat revenue estimates but missed on EPS, while analyst sentiment remains positive with 78.57% buy ratings and a $91.63 consensus target.
The outlook balances growth potential in synthetic biology and AI-driven drug discovery against persistent losses and cash burn. Key risks include execution challenges in achieving profitability and competitive pressures. With the stock near analyst targets, further upside depends on margin improvement and sustained top-line expansion in the genomics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
